{"product_id":"ll-37-peptide-intelligence-monograph-fime","title":"LL-37 Peptide Intelligence Monograph | FIME","description":"\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eHuman Cathelicidin • Innate Immunity • Antimicrobial Defense • Biofilms • Immunomodulation • Wound Biology\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLL-37 is unlike many compounds found in the modern peptide marketplace.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIt is not simply a synthetic molecule developed in a laboratory. \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eLL-37 is part of human biology\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e—a naturally occurring 37-amino-acid host-defense peptide involved in our innate response to microorganisms, inflammation, and tissue injury.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts biology is remarkable.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLL-37 demonstrates experimental antimicrobial activity, participates in immune-cell signaling, influences inflammatory pathways, interacts with biofilm biology, and has been implicated in epithelial repair and wound healing.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eBut fascinating biology creates an equally important question:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eDoes administering LL-37 reproduce the benefits of the LL-37 our bodies naturally produce?\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe answer is far more complicated than many commercial peptide claims suggest.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eFounder’s Institute of Medicine \u0026amp; Education LL-37 Peptide Intelligence Monograph\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e examines that distinction—from molecular biology and biofilms through controlled human clinical trials.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eInside the Monograph\u003c\/span\u003e\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eWhat LL-37 is and where it comes from\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eHuman cathelicidin and innate immunity\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eLL-37 as a host-defense peptide\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eDirect antimicrobial mechanisms\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eAntibacterial, antiviral, and antifungal research\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e\u003cspan\u003eBiofilms and persistent microbial communities\u003c\/span\u003e\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eThe distinction between planktonic killing and anti-biofilm activity\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eImmune modulation and chemotaxis\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eInflammatory signaling\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eWound and epithelial biology\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eHuman topical LL-37 clinical trials\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eThe HEAL LL-37 phase IIb study\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eWhy an encouraging subgroup does not equal a successful overall trial\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eTopical versus systemic evidence\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eLong-term safety limitations\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eLL-37 in inflammatory disease and cancer biology\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eCommercial peptide-market claims\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eProduct quality and regulatory considerations\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eFIME evidence grading and clinical interpretation\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eBiofilms: A Particularly Interesting Frontier\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eBiofilms represent one of the more intriguing areas of LL-37 research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMicroorganisms living within biofilms behave differently from free-floating organisms. They can organize into persistent communities surrounded by an extracellular matrix, altering antimicrobial susceptibility and interactions with host defenses.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eExperimental research suggests LL-37 may influence microbial attachment, motility, biofilm formation, and biofilm-associated behavior.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eBut FIME preserves an essential distinction:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003ePlanktonic antimicrobial activity ≠ anti-biofilm activity ≠ demonstrated treatment of a human biofilm infection.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eBiofilms remain an important area to follow at the intersection of \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003echronic infection, inflammation, impaired healing, and innate immunity\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eFIME Evidence Perspective\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eEndogenous Human Biology:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Strong\u003c\/span\u003e\u003cbr\u003e\u003cstrong\u003e\u003cspan\u003eMechanistic Evidence:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Strong\u003c\/span\u003e\u003cbr\u003e\u003cstrong\u003e\u003cspan\u003ePreclinical Antimicrobial Evidence:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Strong\u003c\/span\u003e\u003cbr\u003e\u003cstrong\u003e\u003cspan\u003ePreclinical Immunomodulatory Evidence:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Strong\u003c\/span\u003e\u003cbr\u003e\u003cstrong\u003e\u003cspan\u003eHuman Topical Safety Evidence:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Moderate\u003c\/span\u003e\u003cbr\u003e\u003cstrong\u003e\u003cspan\u003eHuman Wound-Healing Efficacy:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Low to Moderate \/ Mixed\u003c\/span\u003e\u003cbr\u003e\u003cstrong\u003e\u003cspan\u003eHuman Systemic Efficacy:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Very Low \/ Not Established\u003c\/span\u003e\u003cbr\u003e\u003cstrong\u003e\u003cspan\u003eLong-Term Exogenous Safety:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Not Established\u003c\/span\u003e\u003cbr\u003e\u003cstrong\u003e\u003cspan\u003eCommercial Injectable Product Evidence:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Not Established\u003c\/span\u003e\u003cbr\u003e\u003cstrong\u003e\u003cspan\u003eFDA-Approved Therapeutic Indication:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e None\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eWhy This Monograph Matters\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLL-37 provides an unusually good lesson in the difference between \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003ephysiology and pharmacology\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLL-37 unquestionably participates in human host defense.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts antimicrobial biology is real.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts immunologic activity is substantial.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts relationship with wound healing and biofilms is scientifically compelling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eYet none of those observations automatically establishes that administering synthetic LL-37 is an effective treatment for infection, chronic wounds, inflammatory disease, or generalized “immune optimization.”\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eHuman therapeutic trials have produced \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003elegitimate but mixed evidence\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThat distinction matters.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eEndogenous function is not therapeutic efficacy.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eAntimicrobial activity in a laboratory is not treatment of human infection.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eImmune modulation is not “immune boosting.”\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eNatural occurrence is not proof that exogenous administration is safe.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eThe FIME Standard\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eScience over hype.\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003eEvidence over claims.\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003eIntegrity over revenue.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eVersion 1.0 Final\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003ePublished by the \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eFounder’s Institute of Medicine \u0026amp; Education\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cspan\u003eFor professional education and scientific review. Not individualized medical advice, a prescription, antimicrobial guidance, or a treatment protocol. LL-37 does not have an established FDA-approved therapeutic indication.\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e","brand":"Founder's Institute of Medicine \u0026 Education","offers":[{"title":"Default Title","offer_id":45384913780918,"sku":null,"price":24.95,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0736\/0990\/4310\/files\/ChatGPTImageAug26_2026_11_06_31AM.png?v=1787771336","url":"https:\/\/foundersinstitutemed.org\/products\/ll-37-peptide-intelligence-monograph-fime","provider":"Founder's Institute of Medicine \u0026 Education","version":"1.0","type":"link"}